Root Admin Guide Posted April 10, 2021 Root Admin Report Share Posted April 10, 2021 A paper discusses a "case of a 32-year-old female with ulcerative colitis who developed severe papulopustular dermatitis while undergoing treatment with the Janus kinase (JAK) inhibitor," brand name, Xeljanz, which is reported in Der Hautarzt. Der HautarztGranulomatous rosacea-like dermatitis under therapy with tofacitinib Kristina Neumann, Patrick Terheyden & Diamant Thaçi . Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now